argenx SE (ARGX)Healthcare | Biotechnology | Amsterdam, Netherlands | NasdaqGS
1,023.21 USD
-35.69
(-3.370%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1,023.21 |
Hot Take ↕ | Aug. 22, 2026, 3:28 a.m. EDT
Argenx presents a rare convergence of explosive growth and financial resilience. The company has delivered eight consecutive years of positive annual returns, culminating in a 3094% cumulative gain over the past eight years. Fundamentally, the business is exceptional: revenue is surging at nearly 60% annually, earnings growth is approaching 100%, and the balance sheet is fortified with over $5 billion in cash against minimal debt. While the stock trades near its 52-week high, the momentum remains intact, supported by analyst upgrades and a pending acquisition of Forte Biosciences. Investors should note the absence of a dividend, as capital is being reinvested into R&D and expansion rather than returned to shareholders. The options market reflects this tension, with traders buying protection at lower levels while maintaining bullish exposure at higher targets. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.040937 |
| AutoARIMA | 0.041393 |
| MSTL | 0.043769 |
| AutoTheta | 0.049817 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 8.23 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.558 |
| Revenue per Share | 3.43648 |
| Market Cap | 64,013,033,472 |
| Trailing P/E | 40.32 |
| Forward P/E | 26.08 |
| Beta | -0.04 |
| Profit Margins | 32.27% |
| Website | https://argenx.com |
As of Aug. 22, 2026, 3:28 a.m. EDT: Speculators are positioning for a continued upward trend with significant call interest at distant strikes (1200+), yet they are heavily hedging downside risk with substantial put volume concentrated at lower strikes (400-800). Implied volatility is elevated on deep out-of-the-money puts, suggesting a priced-in fear of a sharp correction despite the strong price action.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.4989878 |
| Address1 | Laarderhoogtweg 25 |
| All Time High | 1,061.57 |
| All Time Low | 17.33 |
| Ask | 995.0 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 346,800 |
| Average Daily Volume3 Month | 339,882 |
| Average Volume | 339,882 |
| Average Volume10Days | 346,800 |
| Beta | -0.04 |
| Bid | 1,043.59 |
| Bid Size | 1 |
| Book Value | 5.3836 |
| City | Amsterdam |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Netherlands |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1,023.21 |
| Current Ratio | 5.123 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1,053.0 |
| Day Low | 1,018.6 |
| Debt To Equity | 0.558 |
| Earnings Call Timestamp End | 1,784,809,800 |
| Earnings Call Timestamp Start | 1,784,809,800 |
| Earnings Growth | 0.952 |
| Earnings Quarterly Growth | 0.922 |
| Earnings Timestamp | 1,792,672,200 |
| Earnings Timestamp End | 1,792,672,200 |
| Earnings Timestamp Start | 1,792,672,200 |
| Ebitda | 1,612,902,016 |
| Ebitda Margins | 0.30344 |
| Enterprise To Ebitda | 988.652 |
| Enterprise To Revenue | 299.992 |
| Enterprise Value | 1,594,598,752,256 |
| Eps Current Year | 29.04117 |
| Eps Forward | 39.23312 |
| Eps Trailing Twelve Months | 25.38 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 906.2694 |
| Fifty Day Average Change | 116.94061 |
| Fifty Day Average Change Percent | 0.12903516 |
| Fifty Two Week Change Percent | 49.89878 |
| Fifty Two Week High | 1,061.57 |
| Fifty Two Week High Change | -38.359924 |
| Fifty Two Week High Change Percent | -0.03613509 |
| Fifty Two Week Low | 661.85 |
| Fifty Two Week Low Change | 361.36005 |
| Fifty Two Week Low Change Percent | 0.5459848 |
| Fifty Two Week Range | 661.85 - 1061.57 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,495,114,200,000 |
| Float Shares | 1,560,649,503 |
| Forward Eps | 39.23312 |
| Forward P E | 26.080261 |
| Free Cashflow | 761,769,024 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,863 |
| Fullday Change | -35.69 |
| Fullday Change Percent | -3.37048 |
| Fullday Price | 1,023.21 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.59067 |
| Gross Profits | 3,139,672,064 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.46202 |
| Implied Shares Outstanding | 62,560,993 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands. |
| Long Name | argenx SE |
| Market | us_market |
| Market Cap | 64,013,033,472 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_62120637 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 1,715,035,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 66,159,519,661 |
| Number Of Analyst Opinions | 23 |
| Open | 1,049.66 |
| Operating Cashflow | 974,192,000 |
| Operating Margins | 0.31992 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.61 |
| Phone | 31 10 703 8441 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 1,023.21 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 1,058.9 |
| Price Eps Current Year | 35.233086 |
| Price Hint | 2 |
| Price To Book | 190.06055 |
| Price To Sales Trailing12 Months | 12.042782 |
| Profit Margins | 0.32265 |
| Quick Ratio | 4.524 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -35.69 |
| Regular Market Change Percent | -3.37048 |
| Regular Market Day High | 1,053.0 |
| Regular Market Day Low | 1,018.6 |
| Regular Market Day Range | 1,018.6 - 1053.0 |
| Regular Market Open | 1,049.66 |
| Regular Market Previous Close | 1,058.9 |
| Regular Market Price | 1,023.21 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 175,511 |
| Return On Assets | 0.11635 |
| Return On Equity | 0.23635 |
| Revenue Growth | 0.593 |
| Revenue Per Share | 3.43648 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 62,560,993 |
| Shares Percent Shares Out | 0.019199999 |
| Shares Short | 1,202,082 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,539,375 |
| Short Name | argenx SE |
| Short Percent Of Float | 0.019199999 |
| Short Ratio | 4.28 |
| Source Interval | 15 |
| Symbol | ARGX |
| Target High Price | 1,450.0 |
| Target Low Price | 900.0 |
| Target Mean Price | 1,175.6086 |
| Target Median Price | 1,150.0 |
| Total Cash | 5,184,000,000 |
| Total Cash Per Share | 3.316 |
| Total Debt | 47,000,000 |
| Total Revenue | 5,315,468,800 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 25.38 |
| Trailing P E | 40.315605 |
| Trailing Peg Ratio | 1.6728 |
| Triggerable | 1 |
| Two Hundred Day Average | 840.3781 |
| Two Hundred Day Average Change | 182.83191 |
| Two Hundred Day Average Change Percent | 0.2175591 |
| Type Disp | Equity |
| Volume | 175,511 |
| Website | https://argenx.com |
| Zip | 1,101 EB |